A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above

drug protocol number
CS-CTP-AD5NCOV-ⅢCo
drug sponsor
MOH / CanSino
drug study
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
drug trial site
King Fahad Medical City (Riyadh)
drug status
Rejected
drug phase